for german title see below

Phase 1

• Conditions: Klebsiella pneumoniae (K. pneumoniae), a gram negative Enterobacteriaceae, is an opportunistic pathogen leading to hospital- and community-acquired infections (urinary tract infections, pneumonia and septicaemia). An effective vaccine could potentially reduce the use of last resort antibiotics by limiting the spread of resistant strains and even prevent infections with pan-resistant isolates, which are not treatable with antibiotics anymore.; MedDRA version: 20.0Level: LLTClassification code 10046859Term: VaccinationSystem Organ Class: 100000004865; Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]

• Registration Number: EUCTR2020-005090-26-DE
• Lead Sponsor: immaTech Biologics AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-04-20
• Last Update Posted: 17 January 2022

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 166

Inclusion Criteria

1. Good general health by medical history, laboratory findings and physical examination before receiving vaccination as judged by the investigator (subjects with a minor controlled illness, such as mild controlled hypertension, asthma or COPD, and without fever may be enrolled at the discretion of the investigator)
2. Subject who is willing and able to comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits)
3. Signed written informed consent obtained from the subject
4. For Step 1 Groups 1 and 2 only: Female or male between 18-40 years (inclusive) of age at the time of the first vaccination
5. For Step 1 Groups 3 to 6, and Step 2: Female or male subjects between 55-70 (inclusive) years of age at the time of first vaccination
6. Female subjects of childbearing potential are eligible, as long as they practice adequate contraceptive measures from 2 months before the first vaccination until 1 month after the last vaccination.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 116
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50

Exclusion Criteria

1. Health condition that, in the opinion of the investigator, may interfere with optimal participation in the study or place the volunteer at increased risk of adverse events (AEs) Study clinicians, in consultation with the principal investigator, will use clinical judgment on a case-by-case basis to assess safety risks under this criterion
2. Any clinically significant deviation from the normal range in biochemistry or hematology blood tests in the opinion of the investigator
3. Clinically significant abnormalities on physical examination
4. Suspected or known hypersensitivity (including allergy) to any of the vaccine components or to medicinal products or medical equipment whose use is foreseen in this study
5. History of allergy to any vaccine
6. Clinical conditions representing a contraindication to intramuscular vaccination and blood draws (e.g. coagulation disorder)
7. Acute or chronic, clinically significant cardiovascular, pulmonary, hepatic or renal abnormality diseases and/or insufficiency as determined by physical examination or laboratory tests. In particular: unstable current or history of coronary artery disease or cardiac insufficiency, uncontrolled hypertension, clinically significant history of myocardial infarction, atrial fibrillation, uncontrolled or clinically significant type 2 diabetes, current or history of rheumatoid arthritis or temporal arteritis, current acute or chronic active pulmonary diseases
Note: Subjects may be on chronic or as needed medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity and do not indicate a worsening of medical diagnosis or condition
8. Known or suspected impairment of immunological function, documented Human Immunodeficiency Virus (HIV) infection, asplenia/splenectomy, or history of autoimmune disease or lymphoprolipherative disorder
9. Positive blood test for HBsAg, HCV, HIV-1/2
10. Positive test for SARS-CoV-2
11. History of systemic administration of immunosuppressive drugs, i.e. corticosteroids, (PO/IV/IM) within the last 4 weeks prior to 1st vaccination or for more than 14 consecutive days within 3 months prior to 1st vaccination until the last blood sampling visit (i.e prednisone or equivalent =20 mg/day). Inhaled and topical steroids are allowed.
12. Administration of antineoplastic and immune-modulating agents or chemotherapy within 90 days prior to informed consent
13. Planned administration of a vaccine not foreseen by the study protocol within 4 weeks prior to 1st vaccination and 4 weeks after last vaccination. Vaccination against seasonal influenza virus (or CoVID vaccine if on the market) is allowed outside of +/- 7 days from each vaccination
14. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational interventional vaccine/product (pharmaceutical product)
15. Body Mass Index (BMI) <19 and >30
16. History of any chronic or progressive disease that according to judgment of the investigator could interfere with the study outcomes or pose a threat to the participant's health
17. Received an investigational or non-registered product (medicinal drug or vaccine), other than the study vaccine within 3 months prior to 1st administration of study vaccine, or planned use during the study perio

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified